explore -WSS

explore

author：fashion 2025-10-02 23:30:59 - browse：7

Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to say someone overpaid?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss how biotech’s downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences’ struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm.

For more on what we cover, here’s more on Gilead; here’s the news on Inhibrx; here’s the latest on biotech venture capital; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Merck drug for rare lung condition set for approval in U.S.

WSS

Ukraine and a new approach to mental health in war

Second xenotransplant done with gene

Emergency workers more likely to restrain Black patients: study

Washington mulls new rules to avert another Change Healthcare

Lasker Awards 2023: Winners in biomedical research

How AI helped researchers track recovery from depression

focus

explore

hotspot

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Hepatitis C has a cure — but many Americans still lack access to it

Food as medicine: Medically tailored meals may get standardized

Guidelines to prevent youth baseball injuries need more muscle

Biotech stock slump in 2023: awaiting the turnaround

Bright Health sells Medicare Advantage business to Molina

Abortion pill Supreme Court ruling could impact entire drug industry

Medical leaders decry Supreme Court decision on affirmative action

Covid vaccine financial winners and losers, from Pfizer to Novavax

entertainment

EpiPen alternative approval delay highlights citizen petition issue

Covid vaccine financial winners and losers, from Pfizer to Novavax

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

CDC advisers recommend seasonal use of Pfizer RSV shot

The Readout: Lenmeldy, GLP

How AI helped researchers track recovery from depression

Wikipedia

hotspot

explore

focus